Sort
4,870 grants matching “glp 1”
Spring System for Permanent Relief of Urinary Obstruction related to Benign Prostatic Hyperplasia
$636,601Nicholas Damiano · Zenflow, Inc. · R44 · FY2017 · DK
Lead optimization of DHODH inhibitors for malaria
$636,297Margaret A. Phillips · Ut Southwestern Medical Center · R01 · FY2013 · AI
A Novel Recombinant Protein Vaccine Against Ricin Toxin
$635,940University Of Texas Sw Med Ctr/Dallas · U01 · FY2003 · AI
Project 3: Primary Prevention and Uterine Preservation in Premenopausal Women with Obesity and Endometrial Hyperplasia/Cancer
$635,886Andrea Hagemann · Washington University · P50 · FY2025 · CA
TARGETING MASH WITH NOVEL SMALL MOLECULE TXNIP INHIBITOR
$635,709Anath Shalev · University Of Alabama At Birmingham · R01 · FY2025 · DK
Development of novel anti-biofilm compounds for treating chronic wounds
$635,323Daina Zeng · Agile Sciences, Inc. · R44 · FY2015 · AI
Long-Term Islet Function and Impact after Total Pancreatectomy with Islet Autotransplant (LIFT)
$635,170Melena D. Bellin · University Of Minnesota · R01 · FY2023 · DK
Validation of Immunometabolic NLRX1 Therapeutics for IBD
$634,825Andrew Leber · Biotherapeutics, Inc. · R44 · FY2020 · DK
A novel, pleiotropic oral drug class that inhibits gut migration of activated T cells
$634,145Scott McNear Thacher · Orphagen Pharmaceuticals · R44 · FY2025 · DK
Neuroprotective role of GLP-1 receptor agonists
$634,082Nigel H. Greig · National Institute On Aging · ZIA · FY2012 · AG
Bumped-Kinase Inhibitor Drug Development for Toxoplasmosis
$634,016Wesley C Van Voorhis · University Of Washington · R01 · FY2022 · HD
Affordable oral delivery of human blood protein drugs bioencapsulated in plant cells
$633,875Henry Daniell · University Of Pennsylvania · R01 · FY2016 · HL
** AWARDS ISSUED PRIOR TO JANUARY 20, 2025, WERE FUNDED UNDER PREVIOUS ADMINISTRATIONS AND MAY NOT REFLECT THE PRIORITIES AND POLICIES OF THE CURRENT ADMINISTRATION.** THIS PROJECTRESPONDS TO USDA-NIFA AFRI FOUNDATION PROGRAM FOR FOOD SAFETY, NUTRITION AND HEALTH IN THE PROGRAM AREA OF FOOD AND HUMAN HEALTH (A1343). WE WILL EXAMINE INTERACTIONS BETWEEN BRASSICA, GUT MICROBIOME (GM) AND GLP-1 SECRETION. BRASSICA VEGETABLES ARE A RICH SOURCE OF GLUCOSINOLATES (GSLS), A GROUP OF SULFUR COMPOUNDS THAT ARE UNIQUE TO THESE VEGETABLES (BROCCOLI, KALE, AND OTHERS). UPON HYDROLYSIS, GSLS ARE CONVERTED TO BIOACTIVE ISOTHIOCYANATES (ITCS). WHEN CONSUMED RAW, GSLS CAN BE CONVERTED TO ITCS BY THE PLANT ENZYME MYROSINASE. HEAT (COOKING) INACTIVATES MYROSINASE, THEN GUT MICROBIOTA (GM) BECOME RESPONSIBLE FOR ANY GSL CONVERSION TO ITCS. WE HYPOTHESIZE THAT NON-ITC PRODUCING PATHWAYS PRESENT IN THE GM ARE COMPETING FOR GSLS AND THUS EXPLAIN THE DRAMATIC INTER-INDIVIDUAL DIFFERENCES SEEN IN ITC PRODUCTION (AIM 1). ONCE THOUGHT TO BE ONLY PRESENT IN THE MOUTH, BITTER-TASTE RECEPTORS (T2RS) ARE NOW FOUND TO BE PRESENT IN MANY TISSUES INCLUDING THE GUT. SINCE GUT T2RS CAN TRIGGER GLP-1 SECRETION AND ITCS CAN SERVE AS T2R AGONISTS, WE HYPOTHESIZE THAT ITCS PRODUCED BY THE GM BIND INTESTINAL T2R(S) TO TRIGGER GLP-1-DEPENDENT CONTROL OF OBESITY AND GLUCOSE HOMEOSTASIS (AIM 2). OPTIMIZING ITC PRODUCTION IN THE GUT, BOTH AMOUNT AND LOCATION, HAS THE POTENTIAL TO REVERSE GLUCOSE INTOLERANCE AND OBESITY IN HUMANS. OUR FINDINGS WILL INFORM THE PUBLIC ABOUT THE HEALTH PROMOTING PROPERTIES OF BRASSICA, EXPLAIN THE VARIATION IN GSL BIOACTIVATION SEEN IN HUMAN STUDIES, WHERE NON-ITC METABOLISM OF GSLS BY GM HAVE BEEN LITTLE CONSIDERED, AND WILL FURTHER INCREASE BRASSICA INTAKE WORLDWIDE.
$633,000University Of Illinois · · FY2023 · National Institute of Food and Agriculture
Changes in neural response to eating after bariatric surgery: MRI results
$632,876Thomas A. Wadden · University Of Pennsylvania · R01 · FY2010 · DK
Overcoming the blood-brain barrier with nanoparticle vaccines against gliomas
$632,873Elias Sayour · University Of Florida · R37 · FY2025 · CA
Nano-scale proteomic analysis: development, implementation, and applications
$632,556Jinqiu Chen · Division Of Basic Sciences - Nci · ZIC · FY2016 · CA
Development of a cell-penetrating beta-catenin antagonist peptide as a therapeutic candidate for Wnt-driven breast cancer
$632,111Jim Rotolo · Sapience Therapeutics, Inc. · R44 · FY2024 · CA
Restoration of Skin Structure and Function Post-Wounding
$631,997Gautam Sudhir Ghatnekar · Xequel Bio, Inc. · R42 · FY2010 · AR
High-Intensity Ultrasound Ablation for Septal Reduction Therapy of Hypertrophic Cardiomyopathy
$631,913Babak Nazer · University Of Washington · R01 · FY2025 · HL
A Novel Xenon Delivery Platform for Cerebroprotection During Stroke
$631,721Keith Booher · Zymo Research Corporation · R42 · FY2024 · NS
Evaluation of the entero-insular (incretin) axis in cystic fibrosis-competitive renewal.
$631,227Andrea Bridget Kelly · Children'S Hosp Of Philadelphia · R01 · FY2024 · DK
RBP2 Biology and Pathobiology
$631,164William S Blaner · Columbia University Health Sciences · R01 · FY2024 · DK
Enhancement of Beta Cell Function with Pharmacologic and Sleep Apnea Treatment
$630,252David A Ehrmann · University Of Chicago · U01 · FY2014 · DK
Definitive Studies For Use Of Galantamine As A Pre-Treatment Countermeasure Again
$630,123Bill Basinger · Countervail Corporation · R44 · FY2015 · NS
A Hypoxia Activated HIF-1 &Inhibitor for Cancer Therapy
$629,796Prolx Pharmaceuticals Corporation · R44 · FY2004 · CA